Key Insights

Highlights

Treatment Research

2 treatments under study, led by Icaritin

Research Leaders

20 sponsors active, led by Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03236636Phase 3UnknownPrimary

The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Showing all 1 trials

Research Network

Common Treatments

  • Icaritin1
  • Huachansu Pian1

Active Sponsors

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences1
  • Beijing Hospital1
  • Anhui Provincial Hospital1
  • Nanfang Hospital, Southern Medical University1
  • Shenyang Sixth People's Hospital1

Top Investigators

  • Yan Sun, MD1

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Shukui Qin1

    NanJing PLA 81 Hospital

Activity Timeline